4 min read
Over the last 7 days, the Australian market has experienced a slight decline of 1.1%, but it remains up by 11% over the past year with earnings expected to grow by 11% annually. In this context, identifying undervalued stocks that have not yet caught up with broader market gains can offer compelling investment opportunities for those looking to capitalize on potential growth.
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Trajan Group Holdings (ASX:TRJ) | A$0.84 | A$1.68 | 49.9% |
| Kogan.com (ASX:KGN) | A$3.92 | A$7.71 | 49.2% |
| Kinatico (ASX:KYP) | A$0.29 | A$0.53 | 45.5% |
| IDP Education (ASX:IEL) | A$5.52 | A$10.71 | 48.5% |
| Fenix Resources (ASX:FEX) | A$0.37 | A$0.68 | 45.2% |
| Elders (ASX:ELD) | A$7.67 | A$14.04 | 45.4% |
| Credit Clear (ASX:CCR) | A$0.24 | A$0.47 | 49.2% |
| CleanSpace Holdings (ASX:CSX) | A$0.80 | A$1.40 | 43% |
| Betmakers Technology Group (ASX:BET) | A$0.17 | A$0.31 | 46% |
| Atlas Arteria (ASX:ALX) | A$5.22 | A$10.16 | 48.6% |
We're going to check out a few of the best picks from our screener tool.
Overview: Atlas Arteria Limited owns, develops, and operates toll roads in France, Germany, and the United States with a market capitalization of A$7.57 billion.
Operations: The company's revenue segments include A$1.74 billion from APRR, A$40.60 million from ADELAC, A$28.40 million from Warnow Tunnel, A$135.90 million from Chicago Skyway, and A$125.40 million from Dulles Greenway.
Estimated Discount To Fair Value: 48.6%
Atlas Arteria is trading at A$5.22, significantly below its estimated fair value of A$10.16, suggesting it is undervalued based on discounted cash flow analysis. Despite a drop in net income from last year, revenue increased to A$77.5 million for H1 2025. The company reaffirmed its dividend guidance of 40 cps, supported by growing free cash flow, although the dividend yield of 7.66% isn't well covered by earnings or cash flows.
-
Our growth report here indicates Atlas Arteria may be poised for an improving outlook.
-
Take a closer look at Atlas Arteria's balance sheet health here in our report.
Overview: Regis Healthcare Limited provides residential aged care services in Australia and has a market cap of A$2.35 billion.
Operations: The company generates revenue of A$1.16 billion from its residential aged care, home care, and retirement living services in Australia.
Estimated Discount To Fair Value: 26.2%
Regis Healthcare is trading at A$7.79, below its estimated fair value of A$10.55, indicating undervaluation based on discounted cash flow analysis. The company reported revenue of A$1.29 billion and net income of A$48.95 million for the fiscal year ending June 2025, marking a return to profitability from a prior net loss. Earnings are projected to grow annually at 17.8%, outpacing the broader Australian market's growth rate, despite recent large one-off items affecting results.
